The clofibrate saga: a retrospective commentary.
作者信息
Oliver Michael
机构信息
University of Edinburgh, UK.
出版信息
Br J Clin Pharmacol. 2012 Dec;74(6):907-10. doi: 10.1111/j.1365-2125.2012.04282.x.
Abstract
摘要
相似文献
1
The clofibrate saga: a retrospective commentary.氯贝丁酯事件：一篇回顾性评论
Br J Clin Pharmacol. 2012 Dec;74(6):907-10. doi: 10.1111/j.1365-2125.2012.04282.x.
2
[Overviews of fibrate].[贝特类药物概述]
Nihon Rinsho. 2001 Mar;59 Suppl 3:609-17.
3
Five-year trial of clofibrate in ischaemic heart disease.
Br Heart J. 1971 Jan;33(1):145.
4
Do lipid lowering drugs reduce the risk of coronary heart disease?
Crit Rev Clin Lab Sci. 1998 Dec;35(6):603-21. doi: 10.1080/10408369891234291.
5
Lipid lowering drugs and coronary heart disease.
Drugs. 1975;10(3):218-25. doi: 10.2165/00003495-197510030-00004.
6
Therapy and clinical trials.
Curr Opin Lipidol. 1997 Dec;8(6):329-31. doi: 10.1097/00041433-199712000-00001.
7
Review of primary prevention trials of coronary heart disease.
Acta Med Scand Suppl. 1985;701:100-28. doi: 10.1111/j.0954-6820.1985.tb08895.x.
8
Reducing cardiac deaths with hypolipidemic drugs.使用降血脂药物降低心脏死亡风险。
Postgrad Med. 1987 Nov 1;82(6):102-12. doi: 10.1080/00325481.1987.11700033.
9
Current and future therapeutic approaches to hyperlipidemia.高脂血症的当前及未来治疗方法。
Adv Pharmacol. 1996;35:79-114. doi: 10.1016/s1054-3589(08)60275-6.
10
Secondary prevention of coronary heart disease: the role of fibric acids.
Circulation. 2000 Jul 4;102(1):2-4. doi: 10.1161/01.cir.102.1.2.
引用本文的文献
1
Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review.用于管理血脂异常的降脂药物：一项叙述性综述。
Cureus. 2024 Jul 23;16(7):e65202. doi: 10.7759/cureus.65202. eCollection 2024 Jul.
2
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia.超越低密度脂蛋白胆固醇：解读残余动脉粥样硬化性心血管疾病风险格局——聚焦高甘油三酯血症
Front Cardiovasc Med. 2024 Aug 7;11:1389106. doi: 10.3389/fcvm.2024.1389106. eCollection 2024.
3
Addressing chemically-induced obesogenic metabolic disruption: selection of chemicals for human PPARα, PPARγ transactivation, and adipogenesis test methods.针对化学诱导的肥胖代谢紊乱的干预：用于人类 PPARα、PPARγ 转录激活和脂肪生成测试方法的化学物质选择。
Front Endocrinol (Lausanne). 2024 Jul 8;15:1401120. doi: 10.3389/fendo.2024.1401120. eCollection 2024.
4
Therapeutic roles of PPARα activation in ocular ischemic diseases.过氧化物酶体增殖物激活受体α（PPARα）激活在眼部缺血性疾病中的治疗作用
Histol Histopathol. 2023 Apr;38(4):391-401. doi: 10.14670/HH-18-542. Epub 2022 Oct 28.
5
The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models.降血脂药物非诺贝特在细胞培养模型中显著降低新冠病毒感染率。
Front Pharmacol. 2021 Aug 6;12:660490. doi: 10.3389/fphar.2021.660490. eCollection 2021.
6
ENGAGE and EMERGE: Truth and consequences?参与和浮现：真相与后果？
Alzheimers Dement. 2021 Apr;17(4):692-695. doi: 10.1002/alz.12286. Epub 2021 Mar 3.
7
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.非诺贝特，一种新型选择性过氧化物酶体增殖物激活受体 α 调节剂：药物概念及其在血脂异常和代谢性疾病中的临床应用。
Curr Atheroscler Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11883-020-0823-5.
8
When the Best of Intentions Leads to Bad Outcomes.当善意导致不良后果时。
Pain Ther. 2019 Jun;8(1):1-4. doi: 10.1007/s40122-019-0120-6. Epub 2019 Apr 2.
9
Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.新型选择性过氧化物酶体增殖物激活受体 α 调节剂 pemafibrate 在血脂异常和代谢性疾病中的临床应用。
J Atheroscler Thromb. 2019 May 1;26(5):389-402. doi: 10.5551/jat.48918. Epub 2019 Mar 30.
10
Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy.临床研究的新兴趋势：对人口健康和卫生政策的影响。
Milbank Q. 2018 Jun;96(2):369-401. doi: 10.1111/1468-0009.12328.
本文引用的文献
1
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.贝特类药物在调节甘油三酯和高密度脂蛋白胆固醇代谢中的作用机制。
Drugs Today (Barc). 2006 Jan;42(1):39-64. doi: 10.1358/dot.2006.42.1.963528.
2
Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity.ML-236A和ML-236B真菌代谢产物对3-羟基-3-甲基戊二酰辅酶A还原酶的竞争性抑制作用，具有降胆固醇活性。
FEBS Lett. 1976 Dec 31;72(2):323-6. doi: 10.1016/0014-5793(76)80996-9.
3
Blood lipids and human atherosclerosis.血脂与人类动脉粥样硬化
Circulation. 1950 Aug;2(2):161-78. doi: 10.1161/01.cir.2.2.161.
4
Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions.人血浆中的蛋白质-脂质关系。II. 动脉粥样硬化及相关病症
Am J Med. 1951 Oct;11(4):480-93. doi: 10.1016/0002-9343(51)90183-0.
5
Reduction of serum-lipid and uric-acid levels by an orally active androsterone.口服活性雄甾酮降低血清脂质和尿酸水平
Lancet. 1962 Jun 23;1(7243):1321-3. doi: 10.1016/s0140-6736(62)92422-4.
6
FURTHER OBSERVATIONS ON THE EFFECTS OF ATROMID AND OF ETHYL CHLOROPHENOXYISOBUTYRATE ON SERUM LIPID LEVELS.安妥明及氯苯丁酯对血清脂质水平影响的进一步观察
J Atheroscler Res. 1963 Sep-Dec;3:427-44. doi: 10.1016/s0368-1319(63)80023-x.
7
Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate.雄酮与氯苯氧异丁酸乙酯口服活性组合的实验评估。
Lancet. 1962 Jun 23;1(7243):1323-6. doi: 10.1016/s0140-6736(62)92423-6.
8
Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate.氯苯丁酯对脂质代谢及分布的影响
Nature. 1962 Jun 9;194:948-9. doi: 10.1038/194948a0.
9
Serum lipoprotein patterns in coronary sclerosis and associated conditions.冠状动脉硬化及相关病症中的血清脂蛋白模式。
Br Heart J. 1955 Jul;17(3):299-302. doi: 10.1136/hrt.17.3.299.
10
The estimation of serum lipoproteins; a micromethod based on zone electrophoresis and cholesterol estimations.血清脂蛋白的测定；一种基于区带电泳和胆固醇测定的微量方法。
Biochem J. 1954 Dec;58(4):680-5. doi: 10.1042/bj0580680.
Zotero 插件